Heartflow Inc. upped the price of shares in its IPO for a second time to $19 on Aug. 7 before opening on the Nasdaq as “HTFL” at $28 and climbing to $31.50 in early trading. The IPO raked in $316.7 million for the 16.67 million shares sold, giving the cardiology company a valuation of $2.27 billion. Read More
The U.S. FDA posted an Aug. 6 early alert regarding the use of the Watchman left atrial appendage device by Boston Scientific Corp., citing instances in which the device’s delivery system is associated with events of embolism. Read More
Just two days after reporting the appointment of a new CEO, Instylla Inc. said it received a premarket approval from the U.S. FDA for its flagship product Embrace hydrogel embolic system. Embrace HES has been approved for the embolization of hypervascular tumors in peripheral arteries. Read More
Med-tech companies brought in $18.11 billion through financings in the first seven months of 2025, marking a modest rebound from the sector’s recent lows. The total surpasses the $11.73 billion raised during the same period in 2023 and slightly edged out the $16.59 billion raised in the same period in 2024. Read More
Shanghai Moyom Biotechnology Co. Ltd. has launched its Aphranel Magiccrystal dermal filler, the first injectable calcium hydroxylapatite microsphere-based dermal filler developed in China, and the company is already expanding globally. Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: BDC Laboratories, Dialcare, Exact Sciences, Freenome, GE Healthcare, Gentuity, Helix, Nanovibronix, Orchestra Biomed, Reshape Lifesciences, Veracyte, Vyome, Zelis. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Instylla, Surgibox, Zien Medical. Read More
